Co-D Therapeutics

Co-D Therapeutics is a private, preclinical oncology biopharmaceutical company based in Madison, Wisconsin. The company is developing first-in-class combination nanomedicines that use a polymeric micelle delivery system to co-formulate and deliver multiple anticancer agents in a single therapeutic product. Its lead program, Triolimus, combines paclitaxel, rapamycin, and 17-AAG and has been positioned initially for angiosarcoma under orphan-drug designation, with additional interest in breast cancer and non-small cell lung cancer. Co-D's strategy is to improve the therapeutic index of combination cancer therapy by reducing carrier-related toxicity, enabling safer dose escalation, and coordinating delivery of synergistic drugs. The company appears to remain a small private venture with limited publicly disclosed pipeline breadth beyond its lead asset.